HomeCompareCYPS vs EQR

CYPS vs EQR: Dividend Comparison 2026

CYPS yields 2000000.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYPS wins by $4.879226400974806e+39M in total portfolio value
10 years
CYPS
CYPS
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full CYPS calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CYPS vs EQR

📍 CYPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYPSEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYPS + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYPS pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYPS
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, CYPS beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYPS + EQR for your $10,000?

CYPS: 50%EQR: 50%
100% EQR50/50100% CYPS
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CYPS
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYPS buys
0
EQR buys
0
No recent congressional trades found for CYPS or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYPSEQR
Forward yield2000000.00%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$4.879226400974806e+39M$40.5K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$3,819.61
Total dividends collected$4.879195005460081e+39M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CYPS vs EQR ($10,000, DRIP)

YearCYPS PortfolioCYPS Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,248$547.57+$200.00MCYPS
2$3,738,731,768,458$3,738,517,757,009.35$12,701$666.53+$3738731.76MCYPS
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,405$814.59+$65315062866.92MCYPS
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,413$999.84+$1066400830062625.00MCYPS
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$18,795$1,232.92+$16272182796453826560.00MCYPS
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$21,639$1,527.95+$2.3205424011366188e+23MCYPS
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$25,057$1,903.80+$3.0927990661046884e+27MCYPS
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$29,197$2,385.87+$3.8524105697352695e+31MCYPS
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$34,250$3,008.70+$4.484688260147987e+35MCYPS
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$40,467$3,819.61+$4.879226400974806e+39MCYPS

CYPS vs EQR: Complete Analysis 2026

CYPSStock

Cyclo3pss Corporation engages in the licensing, manufacture, sale, and installation of ozone food processing products; and ozone washing and laundry sorting and counting systems for commercial and institutional laundries. It also engages in the research and development of technologies for the sterilization and/or disinfection of certain consumer products. The company was founded in 1927 and is based in Salt Lake City, Utah. In July 2002, the Board of Directors of Cyclo3pss determined to suspend all operations of the company immediately due to an inability to locate willing investors and to secure necessary and suitable financing.

Full CYPS Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CYPS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYPS vs SCHDCYPS vs JEPICYPS vs OCYPS vs KOCYPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.